XML 30 R58.htm IDEA: XBRL DOCUMENT v3.20.1
Note 12 - Related Party Transactions (Details Textual)
1 Months Ended 3 Months Ended 12 Months Ended 13 Months Ended
Oct. 01, 2017
CAD ($)
Sep. 30, 2022
CAD ($)
Mar. 31, 2020
USD ($)
a
Mar. 31, 2019
USD ($)
Dec. 31, 2017
USD ($)
Jan. 31, 2018
CAD ($)
Dec. 31, 2019
USD ($)
Dec. 14, 2017
Dec. 02, 2017
Jul. 12, 2017
Area of Land (Acre) | a     10.4              
Operating Lease, Right-of-Use Asset     $ 199,060       $ 229,284      
Operating Lease, Liability, Total     199,470              
Lease Arrangement, 20 North Rear Road [Member]                    
Operating Lease, Monthly Rent     8,719 $ 5,986   $ 4,000        
Lessee, Operating Lease, Term of Contract (Year)           5 years        
Operating Lease, Right-of-Use Asset     55,451 68,547            
Operating Lease, Liability, Total     $ 52,632 $ 65,467            
Lessee, Operating Lease, Discount Rate     8.00% 8.00%            
Leases Office Space from R&D Labs Canada, Inc [Member]                    
Operating Lease, Monthly Rent $ 2,608 $ 3,390                
Operating Lease, Right-of-Use Asset     $ 143,609       160,737      
Operating Lease, Liability, Total     $ 146,838       163,157      
Lessee, Operating Lease, Discount Rate     8.00% 8.00%            
Leases Office Space from R&D Labs Canada, Inc [Member] | General and Administrative Expense [Member]                    
Operating Lease, Expense     $ 6,325 $ 4,978            
Former CEO [Member]                    
Ownership Percentage     5.00%              
Long-term Convertible Notes Payable to Multiple Private Investors [Member]                    
Debt Instrument, Interest Rate, Stated Percentage                   5.00%
CEN Biotech Ukraine [Member] | XN Pharma [Member]                    
Ownership Percentage     49.00%         49.00%    
CEN Biotech Ukraine [Member]                    
Percentage of Related Party's Equity Interest Owned by Director               25.50%    
Business Acquisition, Percentage of Voting Interests Acquired               51.00%    
CEN Biotech Ukraine [Member]                    
Due from Related Parties, Total     $ 1,065,328       1,065,328      
Percentage of Related Party's Equity Interest Owned by Director                 51.00%  
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member]                    
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings         $ 255,141          
Notes Receivable, Related Parties         44,859          
Joseph Byrne [Member]                    
Related Party Transaction, Due from (to) Related Party, Current, Total     (8,347)              
Board Members and Officers [Member] | Consulting Fees [Member]                    
Related Party Transaction, Amounts of Transaction     31,200 $ 31,200            
Due to Related Parties, Total     $ 295,100       $ 263,900      
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member]                    
Notes Payable, Related Parties         $ 300,000